Aryl hydrocarbon receptor deficiency causes the development of chronic obstructive pulmonary disease through the integration of multiple pathogenic mechanisms
© 2021 Federation of American Societies for Experimental Biology..
Emphysema, a component of chronic obstructive pulmonary disease (COPD), is characterized by irreversible alveolar destruction that results in a progressive decline in lung function. This alveolar destruction is caused by cigarette smoke, the most important risk factor for COPD. Only 15%-20% of smokers develop COPD, suggesting that unknown factors contribute to disease pathogenesis. We postulate that the aryl hydrocarbon receptor (AHR), a receptor/transcription factor highly expressed in the lungs, may be a new susceptibility factor whose expression protects against COPD. Here, we report that Ahr-deficient mice chronically exposed to cigarette smoke develop airspace enlargement concomitant with a decline in lung function. Chronic cigarette smoke exposure also increased cleaved caspase-3, lowered SOD2 expression, and altered MMP9 and TIMP-1 levels in Ahr-deficient mice. We also show that people with COPD have reduced expression of pulmonary and systemic AHR, with systemic AHR mRNA levels positively correlating with lung function. Systemic AHR was also lower in never-smokers with COPD. Thus, AHR expression protects against the development of COPD by controlling interrelated mechanisms involved in the pathogenesis of this disease. This study identifies the AHR as a new, central player in the homeostatic maintenance of lung health, providing a foundation for the AHR as a novel therapeutic target and/or predictive biomarker in chronic lung disease.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
---|---|
Enthalten in: |
FASEB journal : official publication of the Federation of American Societies for Experimental Biology - 35(2021), 3 vom: 01. März, Seite e21376 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Guerrina, Necola [VerfasserIn] |
---|
Links: |
---|
Themen: |
138391-32-9 |
---|
Anmerkungen: |
Date Completed 26.07.2021 Date Revised 23.05.2023 published: Print Citation Status MEDLINE |
---|
doi: |
10.1096/fj.202002350R |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM321642430 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM321642430 | ||
003 | DE-627 | ||
005 | 20231225180313.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1096/fj.202002350R |2 doi | |
028 | 5 | 2 | |a pubmed24n1072.xml |
035 | |a (DE-627)NLM321642430 | ||
035 | |a (NLM)33605487 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Guerrina, Necola |e verfasserin |4 aut | |
245 | 1 | 0 | |a Aryl hydrocarbon receptor deficiency causes the development of chronic obstructive pulmonary disease through the integration of multiple pathogenic mechanisms |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 26.07.2021 | ||
500 | |a Date Revised 23.05.2023 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021 Federation of American Societies for Experimental Biology. | ||
520 | |a Emphysema, a component of chronic obstructive pulmonary disease (COPD), is characterized by irreversible alveolar destruction that results in a progressive decline in lung function. This alveolar destruction is caused by cigarette smoke, the most important risk factor for COPD. Only 15%-20% of smokers develop COPD, suggesting that unknown factors contribute to disease pathogenesis. We postulate that the aryl hydrocarbon receptor (AHR), a receptor/transcription factor highly expressed in the lungs, may be a new susceptibility factor whose expression protects against COPD. Here, we report that Ahr-deficient mice chronically exposed to cigarette smoke develop airspace enlargement concomitant with a decline in lung function. Chronic cigarette smoke exposure also increased cleaved caspase-3, lowered SOD2 expression, and altered MMP9 and TIMP-1 levels in Ahr-deficient mice. We also show that people with COPD have reduced expression of pulmonary and systemic AHR, with systemic AHR mRNA levels positively correlating with lung function. Systemic AHR was also lower in never-smokers with COPD. Thus, AHR expression protects against the development of COPD by controlling interrelated mechanisms involved in the pathogenesis of this disease. This study identifies the AHR as a new, central player in the homeostatic maintenance of lung health, providing a foundation for the AHR as a novel therapeutic target and/or predictive biomarker in chronic lung disease | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a ARNT protein, human |2 NLM | |
650 | 7 | |a Receptors, Aryl Hydrocarbon |2 NLM | |
650 | 7 | |a Aryl Hydrocarbon Receptor Nuclear Translocator |2 NLM | |
650 | 7 | |a 138391-32-9 |2 NLM | |
700 | 1 | |a Traboulsi, Hussein |e verfasserin |4 aut | |
700 | 1 | |a Rico de Souza, Angela |e verfasserin |4 aut | |
700 | 1 | |a Bossé, Yohan |e verfasserin |4 aut | |
700 | 1 | |a Thatcher, Thomas H |e verfasserin |4 aut | |
700 | 1 | |a Robichaud, Annette |e verfasserin |4 aut | |
700 | 1 | |a Ding, Jun |e verfasserin |4 aut | |
700 | 1 | |a Li, Pei Z |e verfasserin |4 aut | |
700 | 1 | |a Simon, Leora |e verfasserin |4 aut | |
700 | 1 | |a Pareek, Swati |e verfasserin |4 aut | |
700 | 1 | |a Bourbeau, Jean |e verfasserin |4 aut | |
700 | 1 | |a Tan, Wan C |e verfasserin |4 aut | |
700 | 1 | |a Benedetti, Andrea |e verfasserin |4 aut | |
700 | 1 | |a Obeidat, Ma'en |e verfasserin |4 aut | |
700 | 1 | |a Sin, Don D |e verfasserin |4 aut | |
700 | 1 | |a Brandsma, Corry-Anke |e verfasserin |4 aut | |
700 | 1 | |a Nickle, David C |e verfasserin |4 aut | |
700 | 1 | |a Sime, Patricia J |e verfasserin |4 aut | |
700 | 1 | |a Phipps, Richard P |e verfasserin |4 aut | |
700 | 1 | |a Nair, Parameswaran |e verfasserin |4 aut | |
700 | 1 | |a Zago, Michela |e verfasserin |4 aut | |
700 | 1 | |a Hamid, Qutayba |e verfasserin |4 aut | |
700 | 1 | |a Smith, Benjamin M |e verfasserin |4 aut | |
700 | 1 | |a Eidelman, David H |e verfasserin |4 aut | |
700 | 1 | |a Baglole, Carolyn J |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t FASEB journal : official publication of the Federation of American Societies for Experimental Biology |d 1989 |g 35(2021), 3 vom: 01. März, Seite e21376 |w (DE-627)NLM01261730X |x 1530-6860 |7 nnns |
773 | 1 | 8 | |g volume:35 |g year:2021 |g number:3 |g day:01 |g month:03 |g pages:e21376 |
856 | 4 | 0 | |u http://dx.doi.org/10.1096/fj.202002350R |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 35 |j 2021 |e 3 |b 01 |c 03 |h e21376 |